Nizar Abdelfattah from UCLA David Geffen School of Medicine: Looking at Potential Impact of Medications on Macular Atrophy
Doctors treating patients with age-related macular degeneration face a wide range of complications including the potential dosage for anti-VEGF medications. One question is what role these drugs play in macular atrophy.
Doctors treating patients with age-related macular degeneration face a wide range of complications including the potential dosage for anti-VEGF medications. One question is what role these drugs play in macular atrophy.
Nizar Abdelfattah, MD, from the David Geffen School of Medicine at UCLA discussed the results of one such study during the annual meeting of the American Society of Retina Specialists in San Francisco. Abdelfattah said that while they were looking at whether the medication either caused atrophy or affected its progression they were unable to come up with any definitive answers to either question.
